世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

皮膚糸状菌性爪真菌症治療の世界市場成長(現状と展望)2024-2030年


Global Dermatophytic Onychomycosis Treatment Market Growth (Status and Outlook) 2024-2030

皮膚糸状菌性爪真菌症は、爪白癬としても知られ、爪に輪状感染を引き起こす足の爪や指の爪の真菌症である。 皮膚糸状菌性爪真菌症治療の世界市場規模は、2023年の1億1,750万米ドルから2030年には1億9,550万米ド... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年5月24日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
92 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

皮膚糸状菌性爪真菌症は、爪白癬としても知られ、爪に輪状感染を引き起こす足の爪や指の爪の真菌症である。
皮膚糸状菌性爪真菌症治療の世界市場規模は、2023年の1億1,750万米ドルから2030年には1億9,550万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は7.5%と予測されています。
LPI(エルピーアイ情報)の最新調査レポート「皮膚糸状菌性爪真菌症治療薬産業予測」は、過去の売上高を調べ、2023年の世界の皮膚糸状菌性爪真菌症治療薬の総売上高をレビューし、2024年から2030年までの皮膚糸状菌性爪真菌症治療薬の予測売上高を地域別・市場分野別に包括的に分析しています。皮膚糸状菌性爪真菌症治療の売上高を地域別、市場分野別、サブセクター別に分類し、世界の皮膚糸状菌性爪真菌症治療産業の詳細な分析を百万米ドル単位で提供します。
このインサイトレポートでは、世界の皮膚糸状菌性爪真菌症治療業界を包括的に分析し、製品セグメンテーション、企業形成、収益、市場シェア、最新動向、M&A活動などに関する主要動向を明らかにします。また本レポートでは、皮膚糸状菌性爪真菌症治療薬のポートフォリオと能力、市場参入戦略、市場ポジション、地理的フットプリントに焦点を当て、世界の主要企業の戦略を分析し、加速する世界の皮膚糸状菌性爪真菌症治療薬市場におけるこれらの企業の独自のポジションをより深く理解します。
この調査レポートは、皮膚糸状菌性爪真菌症治療の世界的な展望を形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化して、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の皮膚糸状菌性爪真菌症治療薬の現状と将来の軌道について非常にニュアンスのある見解を提供します。
世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的医薬品が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調しています。
本レポートでは、皮膚糸状菌性爪真菌症治療薬市場の包括的な概要、市場シェア、成長機会を、製品タイプ別、用途別、主要企業別、主要地域別および国別に紹介する。
タイプ別セグメンテーション
全身療法
局所療法
その他
用途別セグメント
病院
皮膚科クリニック
その他
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ボシュ・ヘルス社
ノバルティスAG
ジョンソン・アンド・ジョンソン
ガルデルマS.A.
セルティック・ファーマシューティカルズ
アナコール・ファーマシューティカルズ
モバーグ・ファーマAB
グラクソ・スミスクライン
ファイザー


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dermatophytic Onychomycosis Treatment Market Size 2019-2030
2.1.2 Dermatophytic Onychomycosis Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Dermatophytic Onychomycosis Treatment Segment by Type
2.2.1 Systemic Therapy
2.2.2 Topical Therapy
2.2.3 Others
2.3 Dermatophytic Onychomycosis Treatment Market Size by Type
2.3.1 Dermatophytic Onychomycosis Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Dermatophytic Onychomycosis Treatment Market Size Market Share by Type (2019-2024)
2.4 Dermatophytic Onychomycosis Treatment Segment by Application
2.4.1 Hospitals
2.4.2 Dermatology Clinics
2.4.3 Others
2.5 Dermatophytic Onychomycosis Treatment Market Size by Application
2.5.1 Dermatophytic Onychomycosis Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Dermatophytic Onychomycosis Treatment Market Size Market Share by Application (2019-2024)
3 Dermatophytic Onychomycosis Treatment Market Size by Player
3.1 Dermatophytic Onychomycosis Treatment Market Size Market Share by Players
3.1.1 Global Dermatophytic Onychomycosis Treatment Revenue by Players (2019-2024)
3.1.2 Global Dermatophytic Onychomycosis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Dermatophytic Onychomycosis Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Dermatophytic Onychomycosis Treatment by Regions
4.1 Dermatophytic Onychomycosis Treatment Market Size by Regions (2019-2024)
4.2 Americas Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
4.3 APAC Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
4.4 Europe Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Dermatophytic Onychomycosis Treatment Market Size by Country (2019-2024)
5.2 Americas Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
5.3 Americas Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dermatophytic Onychomycosis Treatment Market Size by Region (2019-2024)
6.2 APAC Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
6.3 APAC Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Dermatophytic Onychomycosis Treatment by Country (2019-2024)
7.2 Europe Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
7.3 Europe Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dermatophytic Onychomycosis Treatment by Region (2019-2024)
8.2 Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Dermatophytic Onychomycosis Treatment Market Forecast
10.1 Global Dermatophytic Onychomycosis Treatment Forecast by Regions (2025-2030)
10.1.1 Global Dermatophytic Onychomycosis Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Dermatophytic Onychomycosis Treatment Forecast
10.1.3 APAC Dermatophytic Onychomycosis Treatment Forecast
10.1.4 Europe Dermatophytic Onychomycosis Treatment Forecast
10.1.5 Middle East & Africa Dermatophytic Onychomycosis Treatment Forecast
10.2 Americas Dermatophytic Onychomycosis Treatment Forecast by Country (2025-2030)
10.2.1 United States Dermatophytic Onychomycosis Treatment Market Forecast
10.2.2 Canada Dermatophytic Onychomycosis Treatment Market Forecast
10.2.3 Mexico Dermatophytic Onychomycosis Treatment Market Forecast
10.2.4 Brazil Dermatophytic Onychomycosis Treatment Market Forecast
10.3 APAC Dermatophytic Onychomycosis Treatment Forecast by Region (2025-2030)
10.3.1 China Dermatophytic Onychomycosis Treatment Market Forecast
10.3.2 Japan Dermatophytic Onychomycosis Treatment Market Forecast
10.3.3 Korea Dermatophytic Onychomycosis Treatment Market Forecast
10.3.4 Southeast Asia Dermatophytic Onychomycosis Treatment Market Forecast
10.3.5 India Dermatophytic Onychomycosis Treatment Market Forecast
10.3.6 Australia Dermatophytic Onychomycosis Treatment Market Forecast
10.4 Europe Dermatophytic Onychomycosis Treatment Forecast by Country (2025-2030)
10.4.1 Germany Dermatophytic Onychomycosis Treatment Market Forecast
10.4.2 France Dermatophytic Onychomycosis Treatment Market Forecast
10.4.3 UK Dermatophytic Onychomycosis Treatment Market Forecast
10.4.4 Italy Dermatophytic Onychomycosis Treatment Market Forecast
10.4.5 Russia Dermatophytic Onychomycosis Treatment Market Forecast
10.5 Middle East & Africa Dermatophytic Onychomycosis Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Dermatophytic Onychomycosis Treatment Market Forecast
10.5.2 South Africa Dermatophytic Onychomycosis Treatment Market Forecast
10.5.3 Israel Dermatophytic Onychomycosis Treatment Market Forecast
10.5.4 Turkey Dermatophytic Onychomycosis Treatment Market Forecast
10.5.5 GCC Countries Dermatophytic Onychomycosis Treatment Market Forecast
10.6 Global Dermatophytic Onychomycosis Treatment Forecast by Type (2025-2030)
10.7 Global Dermatophytic Onychomycosis Treatment Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Bausch Health Companies
11.1.1 Bausch Health Companies Company Information
11.1.2 Bausch Health Companies Dermatophytic Onychomycosis Treatment Product Offered
11.1.3 Bausch Health Companies Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bausch Health Companies Main Business Overview
11.1.5 Bausch Health Companies Latest Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Information
11.2.2 Novartis AG Dermatophytic Onychomycosis Treatment Product Offered
11.2.3 Novartis AG Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Novartis AG Main Business Overview
11.2.5 Novartis AG Latest Developments
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Company Information
11.3.2 Johnson and Johnson Dermatophytic Onychomycosis Treatment Product Offered
11.3.3 Johnson and Johnson Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Johnson and Johnson Main Business Overview
11.3.5 Johnson and Johnson Latest Developments
11.4 Galderma S.A.
11.4.1 Galderma S.A. Company Information
11.4.2 Galderma S.A. Dermatophytic Onychomycosis Treatment Product Offered
11.4.3 Galderma S.A. Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Galderma S.A. Main Business Overview
11.4.5 Galderma S.A. Latest Developments
11.5 Celtic Pharmaceuticals
11.5.1 Celtic Pharmaceuticals Company Information
11.5.2 Celtic Pharmaceuticals Dermatophytic Onychomycosis Treatment Product Offered
11.5.3 Celtic Pharmaceuticals Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Celtic Pharmaceuticals Main Business Overview
11.5.5 Celtic Pharmaceuticals Latest Developments
11.6 Anacor Pharmaceuticals
11.6.1 Anacor Pharmaceuticals Company Information
11.6.2 Anacor Pharmaceuticals Dermatophytic Onychomycosis Treatment Product Offered
11.6.3 Anacor Pharmaceuticals Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Anacor Pharmaceuticals Main Business Overview
11.6.5 Anacor Pharmaceuticals Latest Developments
11.7 Moberg Pharma AB
11.7.1 Moberg Pharma AB Company Information
11.7.2 Moberg Pharma AB Dermatophytic Onychomycosis Treatment Product Offered
11.7.3 Moberg Pharma AB Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Moberg Pharma AB Main Business Overview
11.7.5 Moberg Pharma AB Latest Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Information
11.8.2 GlaxoSmithKline Dermatophytic Onychomycosis Treatment Product Offered
11.8.3 GlaxoSmithKline Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 GlaxoSmithKline Main Business Overview
11.8.5 GlaxoSmithKline Latest Developments
11.9 Pfizer Inc
11.9.1 Pfizer Inc Company Information
11.9.2 Pfizer Inc Dermatophytic Onychomycosis Treatment Product Offered
11.9.3 Pfizer Inc Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Pfizer Inc Main Business Overview
11.9.5 Pfizer Inc Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails.
The global Dermatophytic Onychomycosis Treatment market size is projected to grow from US$ 1175 million in 2023 to US$ 1945.5 million in 2030; it is expected to grow at a CAGR of 7.5% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Dermatophytic Onychomycosis Treatment Industry Forecast” looks at past sales and reviews total world Dermatophytic Onychomycosis Treatment sales in 2023, providing a comprehensive analysis by region and market sector of projected Dermatophytic Onychomycosis Treatment sales for 2024 through 2030. With Dermatophytic Onychomycosis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dermatophytic Onychomycosis Treatment industry.
This Insight Report provides a comprehensive analysis of the global Dermatophytic Onychomycosis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dermatophytic Onychomycosis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dermatophytic Onychomycosis Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dermatophytic Onychomycosis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dermatophytic Onychomycosis Treatment.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Dermatophytic Onychomycosis Treatment market by product type, application, key players and key regions and countries.
Segmentation by type
Systemic Therapy
Topical Therapy
Others
Segmentation by application
Hospitals
Dermatology Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bausch Health Companies
Novartis AG
Johnson and Johnson
Galderma S.A.
Celtic Pharmaceuticals
Anacor Pharmaceuticals
Moberg Pharma AB
GlaxoSmithKline
Pfizer Inc



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dermatophytic Onychomycosis Treatment Market Size 2019-2030
2.1.2 Dermatophytic Onychomycosis Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Dermatophytic Onychomycosis Treatment Segment by Type
2.2.1 Systemic Therapy
2.2.2 Topical Therapy
2.2.3 Others
2.3 Dermatophytic Onychomycosis Treatment Market Size by Type
2.3.1 Dermatophytic Onychomycosis Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Dermatophytic Onychomycosis Treatment Market Size Market Share by Type (2019-2024)
2.4 Dermatophytic Onychomycosis Treatment Segment by Application
2.4.1 Hospitals
2.4.2 Dermatology Clinics
2.4.3 Others
2.5 Dermatophytic Onychomycosis Treatment Market Size by Application
2.5.1 Dermatophytic Onychomycosis Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Dermatophytic Onychomycosis Treatment Market Size Market Share by Application (2019-2024)
3 Dermatophytic Onychomycosis Treatment Market Size by Player
3.1 Dermatophytic Onychomycosis Treatment Market Size Market Share by Players
3.1.1 Global Dermatophytic Onychomycosis Treatment Revenue by Players (2019-2024)
3.1.2 Global Dermatophytic Onychomycosis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Dermatophytic Onychomycosis Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Dermatophytic Onychomycosis Treatment by Regions
4.1 Dermatophytic Onychomycosis Treatment Market Size by Regions (2019-2024)
4.2 Americas Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
4.3 APAC Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
4.4 Europe Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Dermatophytic Onychomycosis Treatment Market Size by Country (2019-2024)
5.2 Americas Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
5.3 Americas Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dermatophytic Onychomycosis Treatment Market Size by Region (2019-2024)
6.2 APAC Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
6.3 APAC Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Dermatophytic Onychomycosis Treatment by Country (2019-2024)
7.2 Europe Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
7.3 Europe Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dermatophytic Onychomycosis Treatment by Region (2019-2024)
8.2 Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Dermatophytic Onychomycosis Treatment Market Forecast
10.1 Global Dermatophytic Onychomycosis Treatment Forecast by Regions (2025-2030)
10.1.1 Global Dermatophytic Onychomycosis Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Dermatophytic Onychomycosis Treatment Forecast
10.1.3 APAC Dermatophytic Onychomycosis Treatment Forecast
10.1.4 Europe Dermatophytic Onychomycosis Treatment Forecast
10.1.5 Middle East & Africa Dermatophytic Onychomycosis Treatment Forecast
10.2 Americas Dermatophytic Onychomycosis Treatment Forecast by Country (2025-2030)
10.2.1 United States Dermatophytic Onychomycosis Treatment Market Forecast
10.2.2 Canada Dermatophytic Onychomycosis Treatment Market Forecast
10.2.3 Mexico Dermatophytic Onychomycosis Treatment Market Forecast
10.2.4 Brazil Dermatophytic Onychomycosis Treatment Market Forecast
10.3 APAC Dermatophytic Onychomycosis Treatment Forecast by Region (2025-2030)
10.3.1 China Dermatophytic Onychomycosis Treatment Market Forecast
10.3.2 Japan Dermatophytic Onychomycosis Treatment Market Forecast
10.3.3 Korea Dermatophytic Onychomycosis Treatment Market Forecast
10.3.4 Southeast Asia Dermatophytic Onychomycosis Treatment Market Forecast
10.3.5 India Dermatophytic Onychomycosis Treatment Market Forecast
10.3.6 Australia Dermatophytic Onychomycosis Treatment Market Forecast
10.4 Europe Dermatophytic Onychomycosis Treatment Forecast by Country (2025-2030)
10.4.1 Germany Dermatophytic Onychomycosis Treatment Market Forecast
10.4.2 France Dermatophytic Onychomycosis Treatment Market Forecast
10.4.3 UK Dermatophytic Onychomycosis Treatment Market Forecast
10.4.4 Italy Dermatophytic Onychomycosis Treatment Market Forecast
10.4.5 Russia Dermatophytic Onychomycosis Treatment Market Forecast
10.5 Middle East & Africa Dermatophytic Onychomycosis Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Dermatophytic Onychomycosis Treatment Market Forecast
10.5.2 South Africa Dermatophytic Onychomycosis Treatment Market Forecast
10.5.3 Israel Dermatophytic Onychomycosis Treatment Market Forecast
10.5.4 Turkey Dermatophytic Onychomycosis Treatment Market Forecast
10.5.5 GCC Countries Dermatophytic Onychomycosis Treatment Market Forecast
10.6 Global Dermatophytic Onychomycosis Treatment Forecast by Type (2025-2030)
10.7 Global Dermatophytic Onychomycosis Treatment Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Bausch Health Companies
11.1.1 Bausch Health Companies Company Information
11.1.2 Bausch Health Companies Dermatophytic Onychomycosis Treatment Product Offered
11.1.3 Bausch Health Companies Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bausch Health Companies Main Business Overview
11.1.5 Bausch Health Companies Latest Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Information
11.2.2 Novartis AG Dermatophytic Onychomycosis Treatment Product Offered
11.2.3 Novartis AG Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Novartis AG Main Business Overview
11.2.5 Novartis AG Latest Developments
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Company Information
11.3.2 Johnson and Johnson Dermatophytic Onychomycosis Treatment Product Offered
11.3.3 Johnson and Johnson Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Johnson and Johnson Main Business Overview
11.3.5 Johnson and Johnson Latest Developments
11.4 Galderma S.A.
11.4.1 Galderma S.A. Company Information
11.4.2 Galderma S.A. Dermatophytic Onychomycosis Treatment Product Offered
11.4.3 Galderma S.A. Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Galderma S.A. Main Business Overview
11.4.5 Galderma S.A. Latest Developments
11.5 Celtic Pharmaceuticals
11.5.1 Celtic Pharmaceuticals Company Information
11.5.2 Celtic Pharmaceuticals Dermatophytic Onychomycosis Treatment Product Offered
11.5.3 Celtic Pharmaceuticals Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Celtic Pharmaceuticals Main Business Overview
11.5.5 Celtic Pharmaceuticals Latest Developments
11.6 Anacor Pharmaceuticals
11.6.1 Anacor Pharmaceuticals Company Information
11.6.2 Anacor Pharmaceuticals Dermatophytic Onychomycosis Treatment Product Offered
11.6.3 Anacor Pharmaceuticals Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Anacor Pharmaceuticals Main Business Overview
11.6.5 Anacor Pharmaceuticals Latest Developments
11.7 Moberg Pharma AB
11.7.1 Moberg Pharma AB Company Information
11.7.2 Moberg Pharma AB Dermatophytic Onychomycosis Treatment Product Offered
11.7.3 Moberg Pharma AB Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Moberg Pharma AB Main Business Overview
11.7.5 Moberg Pharma AB Latest Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Information
11.8.2 GlaxoSmithKline Dermatophytic Onychomycosis Treatment Product Offered
11.8.3 GlaxoSmithKline Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 GlaxoSmithKline Main Business Overview
11.8.5 GlaxoSmithKline Latest Developments
11.9 Pfizer Inc
11.9.1 Pfizer Inc Company Information
11.9.2 Pfizer Inc Dermatophytic Onychomycosis Treatment Product Offered
11.9.3 Pfizer Inc Dermatophytic Onychomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Pfizer Inc Main Business Overview
11.9.5 Pfizer Inc Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/25 10:25

158.38 円

165.32 円

201.48 円

ページTOPに戻る